A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendations

Ayers, Phil; Adams, Stephen; Boullata, Joseph I.; Gervasio, Jane M.; Holcombe, Beverly; Kraft, Michael D.; Marshall, Neil; Neal, Antoinette; Sacks, Gordon S.; Seres, David S.; Worthington, Patricia; Guenter, Peggi

doi:10.1177/0884533614531294

Cited by 63 publications

(194 citation statements)

References 20 publications

Supporting

Mentioning

192

Contrasting

Unclassified

Order By: Relevance

“…The A.S.P.E.N. Clinical Guidelines Recommendation for PN Ordering, Order Review, Compounding, Labeling, and Dispensing recommended standardized commercially available PN products be considered as an available option for patients alongside compounded (customized or standardized) PN formulations to best meet an organization's patient needs 278 . The use of standardized commercially available PN may be considered in ICU patients when the formulation meets the metabolic needs of the patient.…”

Section: H When Indicated Maximize Efficacy Of Pnmentioning

confidence: 99%

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

McClave

Taylor

Martindale

et al. 2016

J Parenter Enteral Nutr

2,569

1,248

View full text Add to dashboard Cite

Section: H When Indicated Maximize Efficacy Of Pnmentioning

confidence: 99%

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

McClave

Taylor

Martindale

et al. 2016

J Parenter Enteral Nutr

2,569

1,248

View full text Add to dashboard Cite

“…In any healthcare environment, patient‐specific, standardized labels for EN express clearly and accurately what the patient is receiving at any time. Having standardized components on a label decreases potential confusion when a patient is transferred to a different unit within a facility or when a new staff member takes over a patient's care 87 . Clear labeling that the container is “Not for IV Use” helps decrease the risk for an enteral misconnection.…”

Section: Section 5 Procure Select/prepare Label and Dispense Enmentioning

confidence: 99%

ASPEN Safe Practices for Enteral Nutrition Therapy

Boullata

Carrera²,

Harvey

et al. 2016

J Parenter Enteral Nutr

Self Cite

334

531

View full text Add to dashboard Cite

Enteral nutrition (EN) is a valuable clinical intervention for patients of all ages in a variety of care settings. Along with its many outcome benefits come the potential for adverse effects. These safety issues are the result of clinical complications and of process-related errors. The latter can occur at any step from patient assessment, prescribing, and order review, to product selection, labeling, and administration. To maximize the benefits of EN while minimizing adverse events requires that a systematic approach of care be in place. This includes open communication, standardization, and incorporation of best practices into the EN process. This document provides recommendations based on the available evidence and expert consensus for safe practices, across each step of the process, for all those involved in caring for patients receiving EN.

show abstract

“…PN is a major source of medication errors, and ≈20%–30% of PN‐related medication errors involve IV lipid emulsions . In accordance with major guidelines and consensus recommendations, standardization of the PN process (including prescription, review, preparation, and administration) is recommended to minimize the potential risks associated with PN …”

Section: Practical Handling Aspectsmentioning

confidence: 99%

Summary of Proceedings and Expert Consensus Statements From the International Summit “Lipids in Parenteral Nutrition”

Martindale

Berlana

Boullata

et al. 2020

J Parenter Enteral Nutr

View full text Add to dashboard Cite

Background The 2018 Lipids in Parenteral Nutrition summit involved a panel of experts in clinical nutrition, lipid metabolism, and pharmacology, to assess the current state of knowledge and develop expert consensus statements regarding the use of intravenous lipid emulsions in various patient populations and clinical settings. The main purpose of the consensus statements is to assist healthcare professionals by providing practical guidance on common clinical questions related to the provision of lipid emulsions as part of parenteral nutrition (PN). Methods The summit was designed to allow interactive discussion and consensus development. The resulting consensus statements represent the collective opinion of the members of the expert panel, which was informed and supported by scientific evidence and clinical experience. Results The current article summarizes the key discussion topics from the summit and provides a set of consensus statements designed to complement existing evidence‐based guidelines. Lipid emulsions are a major component of PN, serving as a condensed source of energy and essential fatty acids. In addition, lipids modulate a variety of biologic functions, including inflammatory and immune responses, coagulation, and cell signaling. A growing body of evidence suggests that lipid emulsions containing ω‐3 fatty acids from fish oil confer important clinical benefits via suppression of inflammatory mediators and activation of pathways involved in the resolution of inflammation. Conclusions This article provides a set of expert consensus statements to complement formal PN guideline recommendations.

show abstract

A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendations

Cited by 63 publications

References 20 publications

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient

ASPEN Safe Practices for Enteral Nutrition Therapy

Summary of Proceedings and Expert Consensus Statements From the International Summit “Lipids in Parenteral Nutrition”

Contact Info

Product

Resources

About